Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge.
Identifieur interne : 001582 ( PubMed/Checkpoint ); précédent : 001581; suivant : 001583Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge.
Auteurs : Andrew S. Herbert [États-Unis] ; Lynn Heffron ; Roy Sundick ; Paul C. RobertsSource :
- Virology journal [ 1743-422X ] ; 2009.
Descripteurs français
- KwdFr :
- Animaux, Anticorps antiviraux (sang), Charge virale, Chiens, Cytokines (génétique), Cytokines (immunologie), Facteurs immunologiques (génétique), Facteurs immunologiques (immunologie), Femelle, Infections à Orthomyxoviridae (), Infections à Orthomyxoviridae (immunologie), Infections à Orthomyxoviridae (virologie), Lignée cellulaire, Lymphocytes auxiliaires Th1 (immunologie), Poumon (virologie), Production d'anticorps (immunologie), Souris, Sous-type H1N1 du virus de la grippe A (génétique), Sous-type H1N1 du virus de la grippe A (immunologie), Sous-type H3N2 du virus de la grippe A (génétique), Sous-type H3N2 du virus de la grippe A (immunologie), Vaccins antigrippaux (immunologie), Vaccins inactivés (immunologie).
- MESH :
- génétique : Cytokines, Facteurs immunologiques, Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A.
- immunologie : Cytokines, Facteurs immunologiques, Infections à Orthomyxoviridae, Lymphocytes auxiliaires Th1, Production d'anticorps, Sous-type H1N1 du virus de la grippe A, Sous-type H3N2 du virus de la grippe A, Vaccins antigrippaux, Vaccins inactivés.
- sang : Anticorps antiviraux.
- virologie : Infections à Orthomyxoviridae, Poumon.
- Animaux, Charge virale, Chiens, Femelle, Infections à Orthomyxoviridae, Lignée cellulaire, Souris.
English descriptors
- KwdEn :
- Animals, Antibodies, Viral (blood), Antibody Formation (immunology), Cell Line, Cytokines (genetics), Cytokines (immunology), Dogs, Female, Immunologic Factors (genetics), Immunologic Factors (immunology), Influenza A Virus, H1N1 Subtype (genetics), Influenza A Virus, H1N1 Subtype (immunology), Influenza A Virus, H3N2 Subtype (genetics), Influenza A Virus, H3N2 Subtype (immunology), Influenza Vaccines (immunology), Lung (virology), Mice, Orthomyxoviridae Infections (immunology), Orthomyxoviridae Infections (prevention & control), Orthomyxoviridae Infections (virology), Th1 Cells (immunology), Vaccines, Inactivated (immunology), Viral Load.
- MESH :
- chemical , blood : Antibodies, Viral.
- chemical , genetics : Cytokines, Immunologic Factors.
- genetics : Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype.
- immunology : Antibody Formation, Cytokines, Immunologic Factors, Influenza A Virus, H1N1 Subtype, Influenza A Virus, H3N2 Subtype, Influenza Vaccines, Orthomyxoviridae Infections, Th1 Cells, Vaccines, Inactivated.
- prevention & control : Orthomyxoviridae Infections.
- virology : Lung, Orthomyxoviridae Infections.
- Animals, Cell Line, Dogs, Female, Mice, Viral Load.
Abstract
Influenza epidemics continue to cause morbidity and mortality within the human population despite widespread vaccination efforts. This, along with the ominous threat of an avian influenza pandemic (H5N1), demonstrates the need for a much improved, more sophisticated influenza vaccine. We have developed an in vitro model system for producing a membrane-bound Cytokine-bearing Influenza Vaccine (CYT-IVAC). Numerous cytokines are involved in directing both innate and adaptive immunity and it is our goal to utilize the properties of individual cytokines and other immunomodulatory proteins to create a more immunogenic vaccine.
DOI: 10.1186/1743-422X-6-42
PubMed: 19393093
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:19393093Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge.</title>
<author><name sortKey="Herbert, Andrew S" sort="Herbert, Andrew S" uniqKey="Herbert A" first="Andrew S" last="Herbert">Andrew S. Herbert</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Molecular Medicine and Infectious Diseases, Department of Biomedical Sciences and Pathobiology, Virginia Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24060, USA. asherbert@vt.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Molecular Medicine and Infectious Diseases, Department of Biomedical Sciences and Pathobiology, Virginia Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24060</wicri:regionArea>
<placeName><region type="state">Virginie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Heffron, Lynn" sort="Heffron, Lynn" uniqKey="Heffron L" first="Lynn" last="Heffron">Lynn Heffron</name>
</author>
<author><name sortKey="Sundick, Roy" sort="Sundick, Roy" uniqKey="Sundick R" first="Roy" last="Sundick">Roy Sundick</name>
</author>
<author><name sortKey="Roberts, Paul C" sort="Roberts, Paul C" uniqKey="Roberts P" first="Paul C" last="Roberts">Paul C. Roberts</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2009">2009</date>
<idno type="RBID">pubmed:19393093</idno>
<idno type="pmid">19393093</idno>
<idno type="doi">10.1186/1743-422X-6-42</idno>
<idno type="wicri:Area/PubMed/Corpus">001768</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001768</idno>
<idno type="wicri:Area/PubMed/Curation">001768</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001768</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001582</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001582</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge.</title>
<author><name sortKey="Herbert, Andrew S" sort="Herbert, Andrew S" uniqKey="Herbert A" first="Andrew S" last="Herbert">Andrew S. Herbert</name>
<affiliation wicri:level="2"><nlm:affiliation>Center for Molecular Medicine and Infectious Diseases, Department of Biomedical Sciences and Pathobiology, Virginia Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24060, USA. asherbert@vt.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Center for Molecular Medicine and Infectious Diseases, Department of Biomedical Sciences and Pathobiology, Virginia Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24060</wicri:regionArea>
<placeName><region type="state">Virginie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Heffron, Lynn" sort="Heffron, Lynn" uniqKey="Heffron L" first="Lynn" last="Heffron">Lynn Heffron</name>
</author>
<author><name sortKey="Sundick, Roy" sort="Sundick, Roy" uniqKey="Sundick R" first="Roy" last="Sundick">Roy Sundick</name>
</author>
<author><name sortKey="Roberts, Paul C" sort="Roberts, Paul C" uniqKey="Roberts P" first="Paul C" last="Roberts">Paul C. Roberts</name>
</author>
</analytic>
<series><title level="j">Virology journal</title>
<idno type="eISSN">1743-422X</idno>
<imprint><date when="2009" type="published">2009</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies, Viral (blood)</term>
<term>Antibody Formation (immunology)</term>
<term>Cell Line</term>
<term>Cytokines (genetics)</term>
<term>Cytokines (immunology)</term>
<term>Dogs</term>
<term>Female</term>
<term>Immunologic Factors (genetics)</term>
<term>Immunologic Factors (immunology)</term>
<term>Influenza A Virus, H1N1 Subtype (genetics)</term>
<term>Influenza A Virus, H1N1 Subtype (immunology)</term>
<term>Influenza A Virus, H3N2 Subtype (genetics)</term>
<term>Influenza A Virus, H3N2 Subtype (immunology)</term>
<term>Influenza Vaccines (immunology)</term>
<term>Lung (virology)</term>
<term>Mice</term>
<term>Orthomyxoviridae Infections (immunology)</term>
<term>Orthomyxoviridae Infections (prevention & control)</term>
<term>Orthomyxoviridae Infections (virology)</term>
<term>Th1 Cells (immunology)</term>
<term>Vaccines, Inactivated (immunology)</term>
<term>Viral Load</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps antiviraux (sang)</term>
<term>Charge virale</term>
<term>Chiens</term>
<term>Cytokines (génétique)</term>
<term>Cytokines (immunologie)</term>
<term>Facteurs immunologiques (génétique)</term>
<term>Facteurs immunologiques (immunologie)</term>
<term>Femelle</term>
<term>Infections à Orthomyxoviridae ()</term>
<term>Infections à Orthomyxoviridae (immunologie)</term>
<term>Infections à Orthomyxoviridae (virologie)</term>
<term>Lignée cellulaire</term>
<term>Lymphocytes auxiliaires Th1 (immunologie)</term>
<term>Poumon (virologie)</term>
<term>Production d'anticorps (immunologie)</term>
<term>Souris</term>
<term>Sous-type H1N1 du virus de la grippe A (génétique)</term>
<term>Sous-type H1N1 du virus de la grippe A (immunologie)</term>
<term>Sous-type H3N2 du virus de la grippe A (génétique)</term>
<term>Sous-type H3N2 du virus de la grippe A (immunologie)</term>
<term>Vaccins antigrippaux (immunologie)</term>
<term>Vaccins inactivés (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Cytokines</term>
<term>Immunologic Factors</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Cytokines</term>
<term>Facteurs immunologiques</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Cytokines</term>
<term>Facteurs immunologiques</term>
<term>Infections à Orthomyxoviridae</term>
<term>Lymphocytes auxiliaires Th1</term>
<term>Production d'anticorps</term>
<term>Sous-type H1N1 du virus de la grippe A</term>
<term>Sous-type H3N2 du virus de la grippe A</term>
<term>Vaccins antigrippaux</term>
<term>Vaccins inactivés</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Antibody Formation</term>
<term>Cytokines</term>
<term>Immunologic Factors</term>
<term>Influenza A Virus, H1N1 Subtype</term>
<term>Influenza A Virus, H3N2 Subtype</term>
<term>Influenza Vaccines</term>
<term>Orthomyxoviridae Infections</term>
<term>Th1 Cells</term>
<term>Vaccines, Inactivated</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à Orthomyxoviridae</term>
<term>Poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Lung</term>
<term>Orthomyxoviridae Infections</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cell Line</term>
<term>Dogs</term>
<term>Female</term>
<term>Mice</term>
<term>Viral Load</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Charge virale</term>
<term>Chiens</term>
<term>Femelle</term>
<term>Infections à Orthomyxoviridae</term>
<term>Lignée cellulaire</term>
<term>Souris</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Influenza epidemics continue to cause morbidity and mortality within the human population despite widespread vaccination efforts. This, along with the ominous threat of an avian influenza pandemic (H5N1), demonstrates the need for a much improved, more sophisticated influenza vaccine. We have developed an in vitro model system for producing a membrane-bound Cytokine-bearing Influenza Vaccine (CYT-IVAC). Numerous cytokines are involved in directing both innate and adaptive immunity and it is our goal to utilize the properties of individual cytokines and other immunomodulatory proteins to create a more immunogenic vaccine.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19393093</PMID>
<DateCompleted><Year>2009</Year>
<Month>06</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>6</Volume>
<PubDate><Year>2009</Year>
<Month>Apr</Month>
<Day>24</Day>
</PubDate>
</JournalIssue>
<Title>Virology journal</Title>
<ISOAbbreviation>Virol. J.</ISOAbbreviation>
</Journal>
<ArticleTitle>Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge.</ArticleTitle>
<Pagination><MedlinePgn>42</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1186/1743-422X-6-42</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Influenza epidemics continue to cause morbidity and mortality within the human population despite widespread vaccination efforts. This, along with the ominous threat of an avian influenza pandemic (H5N1), demonstrates the need for a much improved, more sophisticated influenza vaccine. We have developed an in vitro model system for producing a membrane-bound Cytokine-bearing Influenza Vaccine (CYT-IVAC). Numerous cytokines are involved in directing both innate and adaptive immunity and it is our goal to utilize the properties of individual cytokines and other immunomodulatory proteins to create a more immunogenic vaccine.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">We have evaluated the immunogenicity of inactivated cytokine-bearing influenza vaccines using a mouse model of lethal influenza virus challenge. CYT-IVACs were produced by stably transfecting MDCK cell lines with mouse-derived cytokines (GM-CSF, IL-2 and IL-4) fused to the membrane-anchoring domain of the viral hemagglutinin. Influenza virus replication in these cell lines resulted in the uptake of the bioactive membrane-bound cytokines during virus budding and release. In vivo efficacy studies revealed that a single low dose of IL-2 or IL-4-bearing CYT-IVAC is superior at providing protection against lethal influenza challenge in a mouse model and provides a more balanced Th1/Th2 humoral immune response, similar to live virus infections.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We have validated the protective efficacy of CYT-IVACs in a mammalian model of influenza virus infection. This technology has broad applications in current influenza virus vaccine development and may prove particularly useful in boosting immune responses in the elderly, where current vaccines are minimally effective.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Herbert</LastName>
<ForeName>Andrew S</ForeName>
<Initials>AS</Initials>
<AffiliationInfo><Affiliation>Center for Molecular Medicine and Infectious Diseases, Department of Biomedical Sciences and Pathobiology, Virginia Maryland Regional College of Veterinary Medicine, Virginia Tech, Blacksburg, VA 24060, USA. asherbert@vt.edu</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Heffron</LastName>
<ForeName>Lynn</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sundick</LastName>
<ForeName>Roy</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Roberts</LastName>
<ForeName>Paul C</ForeName>
<Initials>PC</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>R21 AI065591</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>AI065591</GrantID>
<Acronym>AI</Acronym>
<Agency>NIAID NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2009</Year>
<Month>04</Month>
<Day>24</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Virol J</MedlineTA>
<NlmUniqueID>101231645</NlmUniqueID>
<ISSNLinking>1743-422X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015164">Vaccines, Inactivated</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000917" MajorTopicYN="N">Antibody Formation</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004285" MajorTopicYN="N">Dogs</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053118" MajorTopicYN="N">Influenza A Virus, H1N1 Subtype</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D053122" MajorTopicYN="N">Influenza A Virus, H3N2 Subtype</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009976" MajorTopicYN="N">Orthomyxoviridae Infections</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018417" MajorTopicYN="N">Th1 Cells</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015164" MajorTopicYN="N">Vaccines, Inactivated</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year>
<Month>04</Month>
<Day>10</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2009</Year>
<Month>04</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2009</Year>
<Month>4</Month>
<Day>28</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2009</Year>
<Month>4</Month>
<Day>28</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2009</Year>
<Month>6</Month>
<Day>6</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">19393093</ArticleId>
<ArticleId IdType="pii">1743-422X-6-42</ArticleId>
<ArticleId IdType="doi">10.1186/1743-422X-6-42</ArticleId>
<ArticleId IdType="pmc">PMC2679740</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Infect Immun. 2007 Jun;75(6):3102-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17403870</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2007 Aug 18;370(9587):580-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17707753</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2008 Dec;82(23):11813-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18786995</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Interferon Cytokine Res. 2009 Jan;29(1):9-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19014337</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Scand J Immunol. 2004 Jan;59(1):1-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14723616</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2004 Feb 26;350(9):896-903</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14985487</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2004 Feb 21;363(9409):617-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14987888</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2004 Mar 5;303(5663):1526-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14976262</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2004 Mar 12;22(9-10):1199-205</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15003648</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5598-603</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15034168</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2004 Jul;103(1-2):163-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15163505</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biomed Pharmacother. 2004 Jun;58(5):325-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15194169</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2004 Oct 25;328(2):266-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15464846</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br Med Bull. 1979 Jan;35(1):69-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">367490</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 1987 May 22;236(4804):944-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3107127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 1988 Oct;6(5):409-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2848377</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1989 Feb 1;142(3):800-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2783601</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Top Microbiol Immunol. 1989;146:107-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2659262</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Immunol. 1992 Feb;22(2):477-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1537382</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Immunol. 1992 Jul;22(7):1827-34</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1623926</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1992 Aug 1;149(3):981-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1634780</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol Methods. 1994 Apr 15;170(2):211-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8157999</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Trop Med Hyg. 1994;50(4 Suppl):33-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8172330</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 1994 Apr;12(5):419-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8023550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2000 Jun 1;18(24):2713-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10781859</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2000 Aug 15;165(4):1877-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10925267</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2000 Sep 15;19(2-3):217-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10930676</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2000 Sep 18;192(6):823-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10993913</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2001 Jan 1;166(1):633-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11123347</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Rev. 2001 Jan;14(1):129-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11148006</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int Immunol. 2001 Jun;13(6):713-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11369698</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2001 Jun 15;166(12):7381-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11390489</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Res. 2001;23(2-3):179-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11444383</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Immunol. 2001 Aug 1;211(2):143-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11591118</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2002 Jan 31;20(9-10):1340-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11818152</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Gene Ther. 2002 Oct;9(19):1302-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12224013</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunother. 2003 Jan-Feb;26(1):63-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12514430</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2003 Mar 7;21(11-12):1268-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12559808</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 Mar;77(6):3615-23</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12610137</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2003 Jun 2;21(19-20):2362-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12744867</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Cancer. 2004 Feb 20;108(5):696-703</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14696096</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1994 Nov 1;153(9):4029-39</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7930610</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 1994 Aug;12(11):993-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7975853</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1995 Jan;171(1):198-203</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7798664</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1996 Oct 31;383(6603):787-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8893001</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1997 Jun;71(6):4347-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9151823</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1997 Oct 1;159(7):3638-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9317164</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Cancer. 1997 Nov 27;73(5):663-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9398043</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunol Rev. 1997 Oct;159:95-103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9416505</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1998 Jan 5;240(1):127-37</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9448697</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1998 May 12;95(10):5746-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9576955</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1998 May;177(5):1266-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9593011</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1998 Oct;178(4):933-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9806018</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Exp Hematol. 1998 Nov;26(12):1178-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9808058</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 1999 Feb 5;17(5):490-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10073728</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 1999 Mar 5;17(9-10):1223-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10195636</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 1999 Mar 5;17(9-10):1239-50</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10195637</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1999 Sep;180(3):579-85</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10438342</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1999 Oct;180(4):940-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10479116</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 1999 Oct;180(4):1356-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10479172</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Microbiol. 1954 Jun;10(3):457-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">13174769</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2005 Jan 27;352(4):333-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15668219</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 2005 Jun 20;201(12):1899-903</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15967820</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Scand J Immunol. 2005 Jul;62(1):36-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16092921</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>MMWR Morb Mortal Wkly Rep. 2006 Jun 16;55(23):648-53</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16775576</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Wkly Epidemiol Rec. 2006 Jun 30;81(26):249-57</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16812929</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Vaccine Immunol. 2006 Sep;13(9):981-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16960108</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Oncol. 2007 Feb;18(2):226-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17116643</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Virginie</li>
</region>
</list>
<tree><noCountry><name sortKey="Heffron, Lynn" sort="Heffron, Lynn" uniqKey="Heffron L" first="Lynn" last="Heffron">Lynn Heffron</name>
<name sortKey="Roberts, Paul C" sort="Roberts, Paul C" uniqKey="Roberts P" first="Paul C" last="Roberts">Paul C. Roberts</name>
<name sortKey="Sundick, Roy" sort="Sundick, Roy" uniqKey="Sundick R" first="Roy" last="Sundick">Roy Sundick</name>
</noCountry>
<country name="États-Unis"><region name="Virginie"><name sortKey="Herbert, Andrew S" sort="Herbert, Andrew S" uniqKey="Herbert A" first="Andrew S" last="Herbert">Andrew S. Herbert</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001582 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001582 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= PandemieGrippaleV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:19393093 |texte= Incorporation of membrane-bound, mammalian-derived immunomodulatory proteins into influenza whole virus vaccines boosts immunogenicity and protection against lethal challenge. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:19393093" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a PandemieGrippaleV1
![]() | This area was generated with Dilib version V0.6.34. | ![]() |